Neuroendocrine tumors PET: Difference between revisions
Jump to navigation
Jump to search
Matt Pijoan (talk | contribs) Created page with "test" |
Mahshid |
||
| (3 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Neuroendocrine tumors}} | |||
{{CMG}} | |||
== Overview == | |||
==PET-CT Scan== | |||
A [[gallium]]-68 receptor [[positron emission tomography|PET]]-CT, integrating a PET image with a CT image, is much more senstitive than an OctreoScan, and it generates objective (quantified) results in the form of a standardized uptake value (SUV). | |||
==References== | |||
{{Reflist|2}} | |||
[[Category:Needs content]] | |||
[[Category:Disease]] | |||
[[Category:Endocrinology]] | |||
{{WH}} | |||
{{WS}} | |||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Endocrinology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 02:59, 27 November 2017
|
Neuroendocrine tumors Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
PET-CT Scan
A gallium-68 receptor PET-CT, integrating a PET image with a CT image, is much more senstitive than an OctreoScan, and it generates objective (quantified) results in the form of a standardized uptake value (SUV).